Evidence strength for the context described on this page.
PEPTIDE ATLAS / ENERGY & LONGEVITY / ELAMIPRETIDE
EvidenceAccelerated approval; confirmation pendingi
RegulatoryFDA-approvedi
Elamipretide

The first FDA-approved Barth syndrome therapy; approval does not establish general mitochondrial enhancement.
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read the evidence limits
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
The five facts to know first.
Status is product-, formulation- and indication-specific.
Public education does not establish a personal treatment plan.
Plus 0 research searches. A search link is not a cited study or proof of a claim.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗Where present, the date above records an editorial content review, not medical approval or a live check of every claim. Follow the official product label and regulator links for current status. This page does not establish availability through Modern Bio.
How we describe evidence →OVERVIEW
What Elamipretide is.
A mitochondria-targeting tetrapeptide that binds cardiolipin. In 2025 the FDA granted accelerated approval for a narrow rare-disease indication based on an intermediate muscle-strength endpoint.
Targets the inner mitochondrial membrane and cardiolipin with the goal of stabilizing membrane function in Barth syndrome.
Forzinity received accelerated FDA approval to improve muscle strength in patients with Barth syndrome who weigh at least 30 kg. Approval rests on an intermediate endpoint; a confirmatory trial must establish patient benefit. This does not establish general energy or longevity benefits.
Read the FDA approval and evidence requirements ↗This checks the stated regulatory point only, not every clinical claim in the profile.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- Improved knee-extensor muscle strength in the labeled Barth syndrome population weighing at least 30 kg
- Continued approval depends on confirmatory evidence
- General energy enhancement
- Healthy longevity
- Athletic mitochondrial optimization
- Benefit in people without Barth syndrome
Evidence grade: Accelerated approval; confirmation pending. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
CLINICAL CONTEXT
The decision is individual.
Approval applies to a specific product and indication. A licensed clinician must evaluate whether the exact treatment fits your history, current medications and goals.
Identify the outcome, formulation and population actually studied.
Review benefits, uncertainty, contraindications and better-studied alternatives.
A treatment decision needs a responsible clinician, monitoring and a review date.
This public guide does not provide a dosing, injection or self-treatment protocol. Bring the source links and the exact product into a licensed clinical consultation.
MONITORING
What should be tracked.
- Muscle strength and functional outcomes
- Injection-site reactions
- Hypersensitivity
- Disease-specific cardiology and metabolic care
SAFETY
Risks, red flags and reasons to avoid it.
- Injection-site reactions
- Hypersensitivity
- Limited approval population and evidence base
- Unknown benefit-risk for wellness use
- Off-label wellness sourcing
- Products not supplied through the approved prescription chain
- Assuming mitochondrial targeting equals anti-aging
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
SOURCES & RESEARCH LINKS
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. Vendor and community dosing protocols are excluded from this public source list. These are supporting reading links, not a completed claim-by-claim citation map. Search links can lead to changing results; their presence does not establish that a particular study supports this profile.
PRODUCTS & TREATMENT ACCESS
Use a verified prescription pathway.
Specialty prescription product for eligible Barth syndrome patients.
This 2025 approval changed elamipretide's status, but only for a rare disease. It did not validate the broader longevity market built around SS-31.
Learn now. Verify care separately.
This guide is not a booking or prescribing service. Clinical appointments and prescription decisions are handled separately from this educational Atlas.
Review care readiness and standards →NEXT STEP
Return to energy & longevity peptides.
Explore the category →YOUR NEXT STEP
Ready for a clinician-led plan?
Clinical review determines the appropriate next step. No treatment is guaranteed.
THE CARE PATH
We order your labs
A licensed clinician reviews results and recommends a plan
Rx sent directly to you when appropriate
Care depends on eligibility and clinical judgment. No prescription is guaranteed. This pathway is not a recommendation for the treatment or test discussed in this guide.
Start your lab reviewExplore free educational tools